Tarsons Products Ltd - 543399 - Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015, Regarding Equity Investment.
Tarsons Products completed the second tranche of equity infusion, amounting to EUR 552,000, into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd. This capital will be utilized for bank loan repayment, interest, and general corporate purposes of the subsidiary.
Jun 03 2026 19:13:24
Tarsons Products Ltd - 543399 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Tarsons Products has made available the audio recording of its Investor Conference Call, held on May 25, 2026, which discussed the company's Q4 FY26 financial performance. Investors can access the recording on the company's website for detailed insights.
May 25 2026 18:59:43
Tarsons Products Ltd - 543399 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, May 22, 2026
Tarsons Products' board approved FY26 consolidated financial results, with revenue rising 7.7% to ₹4,225.13 mn but net profit decreasing 51.9% to ₹143.22 mn. Grant Thornton Bharat LLP was re-appointed as internal auditor for FY26-27.
May 22 2026 16:09:58
Tarsons Products Ltd - 543399 - Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31, 2026
Tarsons Products announced a board meeting on May 22, 2026, to consider and approve audited Q4 and full FY26 financial results. The board will also review the audit report for the corresponding period and address other business matters.
May 18 2026 16:04:55
Read More